posaconazole ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
systemic antifungal agents, miconazole derivatives 3483 171228-49-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • posaconazole
  • noxafil
  • posaconazol
  • SCH 56592
  • SCH-56592
an antifungal medicine that belongs to the triazole group, it works by preventing the formation of ergosterol, which is an important part of fungal cell walls
  • Molecular weight: 700.79
  • Formula: C37H42F2N8O4
  • CLOGP: 5.32
  • LIPINSKI: 2
  • HAC: 12
  • HDO: 1
  • TPSA: 111.79
  • ALOGS: -4.77
  • ROTB: 12

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 g O
0.30 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 16.31 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 96 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 3.80 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 10.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 23, 2020 PMDA MSD K.K.
April 26, 2019 EMA Accord Healthcare S.L.U.
Sept. 15, 2006 FDA SCHERING

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 476.06 19.87 283 11019 118166 63359554
Pseudoaldosteronism 209.31 19.87 31 11271 44 63477676
Acute myeloid leukaemia 181.34 19.87 79 11223 17068 63460652
Septic shock 136.22 19.87 105 11197 66524 63411196
Neutropenia 133.69 19.87 160 11142 174845 63302875
Drug interaction 130.37 19.87 181 11121 228950 63248770
Graft versus host disease 122.87 19.87 46 11256 6717 63471003
Fusarium infection 115.09 19.87 26 11276 620 63477100
Hepatocellular injury 113.63 19.87 67 11235 27314 63450406
Cholestasis 111.72 19.87 68 11234 29366 63448354
Bronchopulmonary aspergillosis 98.53 19.87 42 11260 8593 63469127
Product use in unapproved indication 96.59 19.87 138 11164 178942 63298778
Mucormycosis 92.72 19.87 30 11272 2841 63474879
Graft versus host disease in gastrointestinal tract 89.15 19.87 30 11272 3211 63474509
Pneumonia fungal 87.91 19.87 34 11268 5421 63472299
Scedosporium infection 80.77 19.87 19 11283 544 63477176
Aspergillus infection 78.15 19.87 35 11267 8058 63469662
Acute myeloid leukaemia recurrent 77.99 19.87 23 11279 1600 63476120
Multiple organ dysfunction syndrome 71.91 19.87 68 11234 56684 63421036
Antibiotic level below therapeutic 71.25 19.87 11 11291 24 63477696
Thrombocytopenia 69.29 19.87 108 11194 151049 63326671
Sepsis 65.49 19.87 106 11196 153017 63324703
Bone marrow failure 63.85 19.87 48 11254 29242 63448478
Differentiation syndrome 63.54 19.87 18 11284 1085 63476635
Cytomegalovirus infection 63.49 19.87 42 11260 20910 63456810
Fungaemia 61.21 19.87 21 11281 2382 63475338
Left atrial hypertrophy 60.26 19.87 10 11292 40 63477680
Adenoviral hepatitis 59.98 19.87 14 11288 387 63477333
Arthralgia 58.08 19.87 15 11287 569695 62908025
Myelosuppression 54.24 19.87 40 11262 23663 63454057
Bicytopenia 52.75 19.87 19 11283 2486 63475234
Blood bilirubin increased 51.87 19.87 47 11255 37093 63440627
Pyrexia 51.57 19.87 192 11110 470286 63007434
Hypokalaemia 51.52 19.87 77 11225 103727 63373993
Respiratory failure 51.19 19.87 76 11226 101782 63375938
Pancytopenia 51.14 19.87 74 11228 96859 63380861
Fatigue 49.90 19.87 51 11251 887977 62589743
Aplasia 49.53 19.87 21 11281 4238 63473482
Electrocardiogram QT prolonged 47.92 19.87 56 11246 59474 63418246
Acute kidney injury 46.71 19.87 127 11175 263288 63214432
Enterococcal infection 45.67 19.87 24 11278 7824 63469896
Hyperbilirubinaemia 45.13 19.87 27 11275 11287 63466433
Sinoatrial block 44.49 19.87 13 11289 875 63476845
Herpes simplex 44.48 19.87 24 11278 8247 63469473
Neurotoxicity 44.20 19.87 31 11271 16959 63460761
Joint swelling 43.74 19.87 4 11298 327662 63150058
Torsade de pointes 43.47 19.87 28 11274 13323 63464397
Electrocardiogram PR shortened 42.96 19.87 10 11292 273 63477447
Pain 42.16 19.87 42 11260 740586 62737134
Staphylococcal sepsis 42.09 19.87 23 11279 8105 63469615
Death 41.97 19.87 154 11148 374227 63103493
Cytokine release syndrome 41.69 19.87 28 11274 14286 63463434
Off label use 40.12 19.87 230 11072 674232 62803488
Graft versus host disease in skin 39.44 19.87 16 11286 2889 63474831
Leukaemia recurrent 39.24 19.87 13 11289 1325 63476395
Cytomegalovirus infection reactivation 37.81 19.87 17 11285 3946 63473774
Systemic candida 37.73 19.87 16 11286 3229 63474491
Gastrointestinal toxicity 37.60 19.87 21 11281 7720 63470000
Hypersensitivity 35.48 19.87 5 11297 292680 63185040
Chronic graft versus host disease 35.09 19.87 15 11287 3087 63474633
Transaminases increased 34.86 19.87 35 11267 31332 63446388
Bacteraemia 34.66 19.87 27 11275 17321 63460399
Acute lymphocytic leukaemia 34.65 19.87 14 11288 2502 63475218
Venoocclusive liver disease 34.59 19.87 17 11285 4818 63472902
Drug hypersensitivity 33.94 19.87 7 11295 310680 63167040
Geotrichum infection 33.12 19.87 9 11293 465 63477255
Adenovirus infection 33.06 19.87 15 11287 3556 63474164
Coagulation test abnormal 32.69 19.87 10 11292 788 63476932
Venous haemorrhage 32.21 19.87 8 11294 289 63477431
Cytopenia 32.13 19.87 22 11280 11579 63466141
Hepatic necrosis 31.98 19.87 17 11285 5670 63472050
Abdominal discomfort 31.59 19.87 9 11293 320876 63156844
BK virus infection 31.08 19.87 14 11288 3265 63474455
Acquired apparent mineralocorticoid excess 30.54 19.87 4 11298 0 63477720
Swelling 30.50 19.87 6 11296 275372 63202348
Allogenic stem cell transplantation 30.20 19.87 6 11296 75 63477645
Fungal infection 30.18 19.87 35 11267 36839 63440881
Mycobacterium abscessus infection 30.12 19.87 9 11293 655 63477065
Disease progression 30.01 19.87 67 11235 122691 63355029
Lung infiltration 29.96 19.87 23 11279 14440 63463280
Endophthalmitis 29.86 19.87 14 11288 3578 63474142
Seroconversion test positive 29.39 19.87 5 11297 24 63477696
Renal tubular acidosis 28.88 19.87 11 11291 1681 63476039
Systemic mycosis 28.70 19.87 10 11292 1187 63476533
Cholecystitis acute 28.57 19.87 18 11284 8242 63469478
Pelvic venous thrombosis 28.49 19.87 11 11291 1744 63475976
Enterobacter test positive 28.37 19.87 7 11295 246 63477474
Pain in extremity 27.99 19.87 12 11290 331474 63146246
Klebsiella infection 27.97 19.87 18 11284 8548 63469172
Long QT syndrome 27.93 19.87 13 11289 3266 63474454
Hepatic failure 27.78 19.87 33 11269 35623 63442097
Organ failure 27.22 19.87 12 11290 2659 63475061
Staphylococcal infection 27.03 19.87 35 11267 41221 63436499
Klebsiella sepsis 26.80 19.87 10 11292 1445 63476275
Enterococcal bacteraemia 26.77 19.87 10 11292 1449 63476271
Brain abscess 26.49 19.87 11 11291 2107 63475613
Growth failure 26.34 19.87 7 11295 332 63477388
Ureaplasma infection 26.00 19.87 8 11294 643 63477077
Graft versus host disease in liver 25.92 19.87 8 11294 649 63477071
Acute lymphocytic leukaemia recurrent 25.76 19.87 11 11291 2258 63475462
Atrioventricular block second degree 25.75 19.87 13 11289 3901 63473819
Neutropenic colitis 25.53 19.87 12 11290 3083 63474637
Graft versus host disease in lung 25.51 19.87 7 11295 375 63477345
Hepatotoxicity 25.17 19.87 32 11270 37009 63440711
Pseudomonal sepsis 25.16 19.87 11 11291 2390 63475330
Acute graft versus host disease in intestine 25.01 19.87 10 11292 1739 63475981
Partial seizures with secondary generalisation 24.97 19.87 7 11295 406 63477314
Depression 24.66 19.87 3 11299 196489 63281231
Disseminated intravascular coagulation 24.44 19.87 23 11279 19028 63458692
Alopecia 24.36 19.87 15 11287 337521 63140199
Posterior reversible encephalopathy syndrome 24.30 19.87 22 11280 17323 63460397
Acute graft versus host disease in skin 24.28 19.87 12 11290 3440 63474280
Malaise 24.27 19.87 23 11279 415931 63061789
Blood lactate dehydrogenase increased 24.24 19.87 25 11277 23091 63454629
Encephalopathy 24.11 19.87 32 11270 38588 63439132
Infusion related reaction 23.95 19.87 7 11295 245514 63232206
Kussmaul respiration 23.38 19.87 6 11296 248 63477472
Overgrowth fungal 23.36 19.87 5 11297 92 63477628
Electrocardiogram ST segment depression 23.25 19.87 11 11291 2866 63474854
Soft tissue infection 23.08 19.87 10 11292 2127 63475593
Dizziness 22.58 19.87 26 11276 429899 63047821
Tumour lysis syndrome 22.45 19.87 16 11286 8974 63468746
Bacterial infection 22.11 19.87 22 11280 19477 63458243
Leukaemia 22.04 19.87 12 11290 4196 63473524
Nodal arrhythmia 21.44 19.87 8 11294 1155 63476565
Atypical pneumonia 21.44 19.87 12 11290 4428 63473292
Cytomegalovirus viraemia 21.28 19.87 13 11289 5636 63472084
Stem cell transplant 21.24 19.87 9 11293 1813 63475907
Rhinovirus infection 21.22 19.87 12 11290 4517 63473203
Cell death 21.19 19.87 10 11292 2591 63475129
Angiokeratoma 21.19 19.87 5 11297 145 63477575
Adenovirus reactivation 21.16 19.87 5 11297 146 63477574
Clostridium difficile colitis 21.13 19.87 22 11280 20547 63457173
Pericardial effusion 20.47 19.87 26 11276 30032 63447688
Escherichia bacteraemia 20.14 19.87 11 11291 3872 63473848
Bacterial sepsis 19.94 19.87 11 11291 3947 63473773
Pruritus 19.91 19.87 21 11281 361432 63116288

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 315.91 17.02 349 15640 136500 34804442
Product use in unapproved indication 230.89 17.02 276 15713 117223 34823719
Aspergillus infection 176.90 17.02 94 15895 12160 34928782
Pseudoaldosteronism 159.05 17.02 28 15961 49 34940893
Bronchopulmonary aspergillosis 135.24 17.02 84 15905 14575 34926367
Septic shock 129.84 17.02 162 15827 71672 34869270
Acute myeloid leukaemia recurrent 127.69 17.02 45 15944 2125 34938817
Graft versus host disease 127.44 17.02 72 15917 10497 34930445
Mucormycosis 125.40 17.02 59 15930 5883 34935059
Fusarium infection 120.63 17.02 37 15952 1123 34939819
Microsporidia infection 120.04 17.02 33 15956 673 34940269
Pneumonia fungal 115.43 17.02 59 15930 7041 34933901
Off label use 105.76 17.02 424 15565 419100 34521842
Neutropenia 104.73 17.02 225 15764 156553 34784389
Acute myeloid leukaemia 102.50 17.02 77 15912 18193 34922749
Drug ineffective 99.11 17.02 441 15548 456310 34484632
Antibiotic level below therapeutic 95.02 17.02 18 15971 56 34940886
Drug resistance 88.57 17.02 82 15907 25845 34915097
Drug interaction 86.81 17.02 263 15726 225683 34715259
Cerebral aspergillosis 85.41 17.02 30 15959 1402 34939540
Pathogen resistance 79.10 17.02 51 15938 9431 34931511
Hepatic cytolysis 76.68 17.02 59 15930 14437 34926505
Systemic mycosis 75.26 17.02 28 15961 1545 34939397
Demodicidosis 70.24 17.02 17 15972 204 34940738
Myositis 70.21 17.02 52 15937 12018 34928924
Acanthamoeba infection 68.54 17.02 19 15970 400 34940542
Cytokine release syndrome 67.97 17.02 67 15922 22810 34918132
Immune effector cell-associated neurotoxicity syndrome 63.68 17.02 32 15957 3681 34937261
Enterococcal infection 63.08 17.02 44 15945 9262 34931680
Fungal infection 57.53 17.02 52 15937 15883 34925059
Cytomegalovirus infection reactivation 56.69 17.02 33 15956 5085 34935857
Graft versus host disease in skin 56.30 17.02 30 15959 3895 34937047
Graft versus host disease in gastrointestinal tract 55.24 17.02 29 15960 3654 34937288
Device related infection 54.04 17.02 52 15937 17185 34923757
Pseudomonas infection 53.98 17.02 45 15944 12337 34928605
Thrombocytopenia 53.53 17.02 175 15814 156072 34784870
Differentiation syndrome 52.40 17.02 21 15968 1417 34939525
Septic embolus 51.45 17.02 20 15969 1245 34939697
Scedosporium infection 50.78 17.02 18 15971 864 34940078
Hypokalaemia 50.08 17.02 93 15896 58121 34882821
Multiple organ dysfunction syndrome 49.95 17.02 109 15880 76457 34864485
Geotrichum infection 47.87 17.02 15 15974 489 34940453
Candida infection 47.34 17.02 49 15940 17666 34923276
Neurotoxicity 46.66 17.02 49 15940 17961 34922981
Fatigue 45.53 17.02 62 15927 370591 34570351
Thrombotic microangiopathy 45.03 17.02 38 15951 10592 34930350
Fall 43.84 17.02 19 15970 202866 34738076
Product use issue 43.52 17.02 92 15897 63124 34877818
Nephropathy toxic 43.33 17.02 40 15949 12548 34928394
Brain abscess 42.34 17.02 23 15966 3102 34937840
Polymyositis 42.06 17.02 18 15971 1435 34939507
Parainfluenzae virus infection 41.63 17.02 22 15967 2808 34938134
Bacteraemia 41.32 17.02 48 15941 19669 34921273
Acute graft versus host disease in skin 40.99 17.02 27 15962 5174 34935768
Eye infection fungal 39.00 17.02 12 15977 368 34940574
Sepsis 38.94 17.02 165 15824 166396 34774546
Arthralgia 38.21 17.02 15 15974 170026 34770916
Graft versus host disease in liver 37.47 17.02 16 15973 1268 34939674
NPM1 gene mutation 36.52 17.02 9 15980 117 34940825
Hyperbilirubinaemia 35.29 17.02 41 15948 16802 34924140
Malaise 34.76 17.02 21 15968 185804 34755138
Pyrexia 34.47 17.02 265 15724 332748 34608194
Central nervous system lesion 33.50 17.02 26 15963 6437 34934505
Pancytopenia 32.90 17.02 107 15882 95050 34845892
Condition aggravated 32.26 17.02 173 15816 192023 34748919
Bronchiolitis obliterans syndrome 32.13 17.02 9 15980 197 34940745
Neutropenic infection 31.98 17.02 15 15974 1483 34939459
Pain 31.96 17.02 28 15961 204647 34736295
Dizziness 31.65 17.02 32 15957 218489 34722453
Chimerism 30.66 17.02 9 15980 234 34940708
Immunosuppressant drug level increased 30.61 17.02 24 15965 6031 34934911
Retinal ischaemia 30.52 17.02 10 15979 377 34940565
Dyspnoea 30.45 17.02 81 15908 376701 34564241
Sinusitis fungal 30.28 17.02 11 15978 567 34940375
Neutrophil Pelger-Huet anomaly present 30.23 17.02 9 15980 246 34940696
Tumour lysis syndrome 29.99 17.02 38 15951 17021 34923921
Treatment failure 29.88 17.02 66 15923 46631 34894311
Brain herniation 29.64 17.02 20 15969 3988 34936954
Product dose omission issue 29.57 17.02 9 15980 119702 34821240
Fungal skin infection 29.21 17.02 17 15972 2617 34938325
Neutropenic colitis 28.93 17.02 18 15971 3126 34937816
Ecthyma 28.58 17.02 10 15979 462 34940480
Myocardial infarction 28.33 17.02 10 15979 121075 34819867
Inappropriate antidiuretic hormone secretion 28.32 17.02 32 15957 12721 34928221
Cholestasis 28.27 17.02 47 15942 26901 34914041
Acquired apparent mineralocorticoid excess 27.69 17.02 6 15983 42 34940900
Staphylococcal bacteraemia 27.44 17.02 26 15963 8426 34932516
Cardioactive drug level increased 27.12 17.02 14 15975 1703 34939239
Staphylococcal infection 26.49 17.02 51 15938 32709 34908233
Depression 26.45 17.02 6 15983 97092 34843850
Lip squamous cell carcinoma 26.33 17.02 7 15982 125 34940817
Necrotising retinitis 26.26 17.02 11 15978 831 34940111
Lower respiratory tract infection fungal 25.95 17.02 10 15979 608 34940334
Incorrect product formulation administered 25.83 17.02 5 15984 18 34940924
Escherichia bacteraemia 25.78 17.02 17 15972 3263 34937679
Acute graft versus host disease in liver 25.40 17.02 13 15976 1553 34939389
Skin necrosis 24.94 17.02 21 15968 5832 34935110
Blood pressure increased 24.90 17.02 5 15984 88097 34852845
Ileus paralytic 24.50 17.02 21 15968 5976 34934966
Stenotrophomonas infection 24.42 17.02 14 15975 2096 34938846
Drug ineffective for unapproved indication 24.39 17.02 41 15948 23674 34917268
Hyperhidrosis 24.32 17.02 3 15986 75689 34865253
Brain compression 24.03 17.02 7 15982 177 34940765
Steroid diabetes 23.90 17.02 14 15975 2181 34938761
Cytopenia 23.41 17.02 29 15960 12694 34928248
Cytomegalovirus infection 22.76 17.02 42 15947 26093 34914849
Cerebral artery embolism 22.45 17.02 10 15979 878 34940064
Septic encephalopathy 22.42 17.02 6 15983 110 34940832
Weight decreased 22.07 17.02 29 15960 176272 34764670
Drug hypersensitivity 21.88 17.02 5 15984 80524 34860418
Encephalopathy 21.56 17.02 49 15940 35270 34905672
Enterobacter bacteraemia 21.45 17.02 8 15981 444 34940498
Pruritus 21.45 17.02 20 15969 141961 34798981
Acute graft versus host disease in intestine 21.20 17.02 14 15975 2694 34938248
Gastrointestinal tract mucosal pigmentation 20.83 17.02 8 15981 482 34940460
Primary adrenal insufficiency 20.81 17.02 5 15984 58 34940884
Folliculitis 20.74 17.02 17 15972 4549 34936393
Nocardiosis 20.71 17.02 16 15973 3935 34937007
Lymphopenia 20.60 17.02 31 15958 16304 34924638
Renal tubular disorder 20.49 17.02 17 15972 4626 34936316
Blood immunoglobulin G decreased 20.40 17.02 11 15978 1462 34939480
Gastrointestinal wall thinning 20.33 17.02 4 15985 16 34940926
Cerebral ventricle collapse 20.08 17.02 5 15984 68 34940874
Necrotising ulcerative gingivostomatitis 19.95 17.02 5 15984 70 34940872
Hyperleukocytosis 19.80 17.02 12 15977 1990 34938952
Respiratory failure 19.74 17.02 100 15889 108472 34832470
Viral haemorrhagic cystitis 19.74 17.02 10 15979 1170 34939772
Intracranial mass 19.72 17.02 10 15979 1172 34939770
Muscle spasms 19.70 17.02 5 15984 74996 34865946
CARD9 deficiency 19.60 17.02 4 15985 20 34940922
Gastroenteritis clostridial 19.38 17.02 7 15982 355 34940587
Systemic candida 19.33 17.02 15 15974 3711 34937231
Hepatotoxicity 19.30 17.02 35 15954 21450 34919492
Donor leukocyte infusion 18.99 17.02 4 15985 24 34940918
Posterior reversible encephalopathy syndrome 18.82 17.02 23 15966 9931 34931011
SARS-CoV-2 RNA 18.10 17.02 4 15985 31 34940911
Stupor 18.04 17.02 13 15976 2878 34938064
Microsporum infection 17.99 17.02 4 15985 32 34940910
Chronic graft versus host disease in eye 17.96 17.02 5 15984 107 34940835
Drug level decreased 17.96 17.02 20 15969 7826 34933116
Bordetella infection 17.91 17.02 5 15984 108 34940834
Insomnia 17.71 17.02 13 15976 103894 34837048
Abscess fungal 17.65 17.02 6 15983 254 34940688
Hypomagnesaemia 17.64 17.02 34 15955 21817 34919125
Sinusitis bacterial 17.57 17.02 7 15982 465 34940477
Acute graft versus host disease 17.39 17.02 18 15971 6485 34934457
Aspergillus test positive 17.25 17.02 7 15982 488 34940454
Pulmonary mass 17.14 17.02 25 15964 12787 34928155

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 729.00 16.94 595 24741 230404 79488648
Pseudoaldosteronism 344.89 16.94 58 25278 118 79718934
Product use in unapproved indication 335.82 16.94 405 24931 249954 79469098
Neutropenia 253.06 16.94 379 24957 287331 79431721
Septic shock 252.41 16.94 249 25087 122552 79596500
Aspergillus infection 241.11 16.94 119 25217 19042 79700010
Mucormycosis 235.79 16.94 92 25244 8377 79710675
Acute myeloid leukaemia 221.19 16.94 132 25204 30753 79688299
Pneumonia fungal 207.61 16.94 91 25245 11119 79707933
Bronchopulmonary aspergillosis 204.51 16.94 112 25224 22182 79696870
Graft versus host disease 200.06 16.94 97 25239 14929 79704123
Drug interaction 198.81 16.94 419 24917 414764 79304288
Fusarium infection 195.81 16.94 55 25281 1777 79717275
Acute myeloid leukaemia recurrent 174.46 16.94 58 25278 3325 79715727
Scedosporium infection 125.07 16.94 37 25299 1441 79717611
Microsporidia infection 121.69 16.94 33 25303 933 79718119
Arthralgia 115.87 16.94 21 25315 571782 79147270
Graft versus host disease in gastrointestinal tract 115.75 16.94 51 25285 6305 79712747
Cholestasis 115.04 16.94 110 25226 51999 79667053
Multiple organ dysfunction syndrome 110.54 16.94 162 25174 120084 79598968
Thrombocytopenia 109.96 16.94 253 25083 265006 79454046
Cytokine release syndrome 109.30 16.94 91 25245 35907 79683145
Sepsis 103.00 16.94 249 25087 269179 79449873
Differentiation syndrome 101.78 16.94 36 25300 2488 79716564
Systemic mycosis 99.86 16.94 36 25300 2630 79716422
Enterococcal infection 99.44 16.94 62 25274 15598 79703454
Pathogen resistance 96.71 16.94 59 25277 14283 79704769
Hypokalaemia 93.94 16.94 166 25170 143874 79575178
Off label use 93.68 16.94 548 24788 906667 78812385
Fatigue 93.42 16.94 95 25241 929632 78789420
Pain 87.89 16.94 58 25278 703744 79015308
Hepatic cytolysis 87.36 16.94 71 25265 27080 79691972
Graft versus host disease in skin 86.27 16.94 41 25295 6032 79713020
Neurotoxicity 86.08 16.94 76 25260 32442 79686610
Drug ineffective 85.88 16.94 611 24725 1080302 78638750
Immune effector cell-associated neurotoxicity syndrome 84.66 16.94 40 25296 5808 79713244
Drug resistance 83.62 16.94 84 25252 42129 79676923
Geotrichum infection 80.58 16.94 24 25312 957 79718095
Pyrexia 80.56 16.94 426 24910 678283 79040769
Cytomegalovirus infection reactivation 80.49 16.94 44 25292 8672 79710380
Device related infection 76.82 16.94 73 25263 34221 79684831
Acanthamoeba infection 76.68 16.94 20 25316 485 79718567
Cytomegalovirus infection 75.70 16.94 80 25256 42564 79676488
Demodicidosis 75.36 16.94 17 25319 218 79718834
Fungal infection 75.32 16.94 79 25257 41669 79677383
Hepatocellular injury 75.25 16.94 84 25252 47509 79671543
Pseudomonas infection 74.39 16.94 58 25278 20845 79698207
Pancytopenia 74.07 16.94 163 25173 165582 79553470
Hyperbilirubinaemia 72.39 16.94 61 25275 24457 79694595
Brain abscess 69.12 16.94 33 25303 4903 79714149
Bacteraemia 68.12 16.94 67 25269 32757 79686295
Myositis 67.81 16.94 53 25283 19115 79699937
Hypersensitivity 67.30 16.94 4 25332 262235 79456817
Cerebral aspergillosis 66.32 16.94 24 25312 1772 79717280
Respiratory failure 65.65 16.94 164 25172 180747 79538305
Graft versus host disease in liver 63.13 16.94 23 25313 1731 79717321
Malaise 62.93 16.94 39 25297 489830 79229222
Joint swelling 61.95 16.94 9 25327 288637 79430415
Fungaemia 59.18 16.94 29 25307 4562 79714490
Staphylococcal infection 58.60 16.94 82 25254 58213 79660839
Drug hypersensitivity 58.28 16.94 12 25324 298904 79420148
Thrombotic microangiopathy 57.12 16.94 49 25287 20120 79698932
Nasopharyngitis 56.66 16.94 7 25329 253874 79465178
Dyspnoea 56.09 16.94 118 25218 856907 78862145
Acquired apparent mineralocorticoid excess 55.97 16.94 10 25326 33 79719019
Dizziness 54.77 16.94 52 25284 526389 79192663
Bone marrow failure 54.54 16.94 74 25262 51033 79668019
Rheumatoid arthritis 54.03 16.94 3 25333 208467 79510585
Tumour lysis syndrome 53.69 16.94 51 25285 23888 79695164
Abdominal discomfort 53.38 16.94 8 25328 250719 79468333
Fall 53.30 16.94 46 25290 487583 79231469
Left atrial hypertrophy 52.65 16.94 10 25326 50 79719002
Systemic candida 51.49 16.94 30 25306 6676 79712376
Cytopenia 50.69 16.94 46 25290 20337 79698715
Neutropenic colitis 50.47 16.94 28 25308 5679 79713373
Nephropathy toxic 48.67 16.94 45 25291 20374 79698678
Candida infection 48.05 16.94 60 25276 38154 79680898
Aplasia 47.23 16.94 30 25306 7790 79711262
Venoocclusive liver disease 47.03 16.94 35 25301 11736 79707316
Escherichia bacteraemia 46.83 16.94 28 25308 6534 79712518
Septic embolus 45.74 16.94 19 25317 2032 79717020
Acute graft versus host disease in skin 45.31 16.94 29 25307 7629 79711423
NPM1 gene mutation 44.20 16.94 10 25326 130 79718922
Depression 43.73 16.94 8 25328 216782 79502270
Pruritus 43.38 16.94 37 25299 394611 79324441
Leukaemia recurrent 43.33 16.94 20 25316 2754 79716298
Blood pressure increased 42.20 16.94 8 25328 211352 79507700
Staphylococcal sepsis 42.16 16.94 36 25300 14690 79704362
Acute graft versus host disease in intestine 41.80 16.94 22 25314 4019 79715033
Encephalopathy 41.74 16.94 76 25260 67321 79651731
BK virus infection 41.63 16.94 29 25307 8775 79710277
Swelling 41.61 16.94 9 25327 216702 79502350
Electrocardiogram QT prolonged 41.60 16.94 90 25246 90296 79628756
Infusion related reaction 41.39 16.94 11 25325 230226 79488826
Stenotrophomonas infection 40.34 16.94 21 25315 3752 79715300
Transaminases increased 39.47 16.94 64 25272 51679 79667373
Renal tubular disorder 39.47 16.94 25 25311 6461 79712591
Klebsiella infection 38.16 16.94 35 25301 15685 79703367
Myelosuppression 38.01 16.94 55 25281 40241 79678811
Pneumonia 37.29 16.94 346 24990 659900 79059152
Ileus paralytic 37.09 16.94 28 25308 9592 79709460
Chimerism 36.76 16.94 10 25326 286 79718766
Graft versus host disease in lung 36.74 16.94 13 25323 899 79718153
Adenoviral hepatitis 36.53 16.94 13 25323 914 79718138
Immunosuppressant drug level increased 36.42 16.94 27 25309 9000 79710052
Electrocardiogram PR shortened 36.15 16.94 10 25326 305 79718747
Bacterial infection 35.99 16.94 47 25289 31233 79687819
Inappropriate antidiuretic hormone secretion 35.81 16.94 43 25293 26270 79692782
Polymyositis 35.65 16.94 18 25318 3018 79716034
Pain in extremity 35.59 16.94 38 25298 364500 79354552
Bronchiolitis obliterans syndrome 35.42 16.94 10 25326 329 79718723
Eye infection fungal 35.16 16.94 11 25325 518 79718534
Drug ineffective for unapproved indication 34.59 16.94 60 25276 51178 79667874
Posterior reversible encephalopathy syndrome 34.22 16.94 42 25294 26239 79692813
Peripheral swelling 33.84 16.94 22 25314 269595 79449457
Neutropenic infection 33.30 16.94 16 25320 2411 79716641
Staphylococcal bacteraemia 33.21 16.94 29 25307 12189 79706863
Weight decreased 32.52 16.94 39 25297 355159 79363893
Parainfluenzae virus infection 32.34 16.94 21 25315 5661 79713391
Lung infiltration 32.09 16.94 38 25298 22874 79696178
Muscle spasms 32.06 16.94 8 25328 174722 79544330
Hyperhidrosis 31.85 16.94 5 25331 151487 79567565
Weight increased 31.71 16.94 25 25311 277361 79441691
Klebsiella sepsis 31.65 16.94 17 25319 3235 79715817
Renal failure 31.55 16.94 137 25199 200831 79518221
Sinusitis fungal 30.61 16.94 15 25321 2359 79716693
Injection site pain 30.42 16.94 3 25333 129835 79589217
Neutrophil Pelger-Huet anomaly present 30.23 16.94 9 25327 358 79718694
Enterococcal bacteraemia 29.75 16.94 16 25320 3052 79716000
Adenovirus reactivation 29.72 16.94 9 25327 380 79718672
Asthma 29.46 16.94 4 25332 135091 79583961
Hepatotoxicity 29.41 16.94 56 25280 51296 79667756
Brain herniation 29.39 16.94 22 25314 7441 79711611
Herpes simplex 29.32 16.94 27 25309 12160 79706892
Discomfort 29.17 16.94 3 25333 125614 79593438
Drug level decreased 29.14 16.94 29 25307 14373 79704679
Central nervous system lesion 29.07 16.94 28 25308 13340 79705712
Long QT syndrome 29.06 16.94 20 25316 5935 79713117
Product dose omission issue 28.68 16.94 22 25314 247515 79471537
Acute kidney injury 28.67 16.94 271 25065 519133 79199919
Bicytopenia 28.41 16.94 18 25318 4652 79714400
Pseudomonal sepsis 28.41 16.94 20 25316 6154 79712898
Acute lymphocytic leukaemia recurrent 28.22 16.94 18 25318 4706 79714346
Cytomegalovirus viraemia 28.15 16.94 27 25309 12794 79706258
Product administered to patient of inappropriate age 27.93 16.94 19 25317 5534 79713518
Feeling abnormal 27.86 16.94 8 25328 159191 79559861
Anxiety 27.65 16.94 23 25313 248489 79470563
Retinal ischaemia 27.13 16.94 10 25326 778 79718274
Torsade de pointes 27 16.94 32 25304 19280 79699772
Adenovirus infection 26.98 16.94 22 25314 8425 79710627
Nausea 26.95 16.94 186 25150 957010 78762042
Chronic graft versus host disease 26.73 16.94 20 25316 6761 79712291
Venous haemorrhage 26.23 16.94 8 25328 346 79718706
Mycobacterium abscessus infection 26.18 16.94 11 25325 1211 79717841
Blood bilirubin increased 26.07 16.94 62 25274 66170 79652882
Necrotising retinitis 25.98 16.94 11 25325 1234 79717818
Lower respiratory tract infection fungal 25.96 16.94 10 25326 878 79718174
Enterobacter bacteraemia 25.92 16.94 10 25326 882 79718170
Insomnia 25.70 16.94 24 25312 245146 79473906
Organ failure 25.68 16.94 16 25320 4017 79715035
Blood immunoglobulin G decreased 25.51 16.94 15 25321 3394 79715658
Musculoskeletal stiffness 25.24 16.94 12 25324 174996 79544056
Nocardiosis 25.21 16.94 18 25318 5661 79713391
Alopecia 25.02 16.94 22 25314 231333 79487719
Hepatic failure 24.85 16.94 58 25278 61154 79657898
Hypoaesthesia 24.81 16.94 13 25323 179339 79539713
Pneumonia klebsiella 24.72 16.94 17 25319 5037 79714015
Cardioactive drug level increased 24.34 16.94 15 25321 3694 79715358
Rash 24.29 16.94 98 25238 578260 79140792
Growth failure 24.27 16.94 7 25329 249 79718803
Hypomagnesaemia 24.25 16.94 49 25287 46862 79672190
Product use issue 24.24 16.94 131 25205 209691 79509361
Fungal skin infection 24.23 16.94 18 25318 6018 79713034
Leukoencephalopathy 23.96 16.94 20 25316 7909 79711143
Microsporum infection 23.78 16.94 5 25331 45 79719007
Seroconversion test positive 23.68 16.94 5 25331 46 79719006
Septic encephalopathy 23.67 16.94 7 25329 272 79718780
Gastrointestinal toxicity 23.57 16.94 20 25316 8089 79710963
Viral haemorrhagic cystitis 23.56 16.94 12 25324 2049 79717003
Disease progression 23.29 16.94 118 25218 184244 79534808
Lip squamous cell carcinoma 22.90 16.94 7 25329 305 79718747
Acute lymphocytic leukaemia 22.64 16.94 16 25320 4953 79714099
Death 22.60 16.94 277 25059 566237 79152815
Headache 22.58 16.94 119 25217 653653 79065399
Steroid diabetes 22.55 16.94 14 25322 3492 79715560
Pneumonia pseudomonal 22.33 16.94 17 25319 5894 79713158
Back pain 22.32 16.94 39 25297 304141 79414911
Clostridium difficile colitis 22.04 16.94 38 25298 32245 79686807
Coagulation test abnormal 21.96 16.94 10 25326 1335 79717717
Cerebral artery embolism 21.58 16.94 11 25325 1880 79717172
Hepatic necrosis 21.58 16.94 20 25316 9080 79709972
Blast cell count decreased 21.23 16.94 4 25332 19 79719033
CARD9 deficiency 21.06 16.94 4 25332 20 79719032
Gastrointestinal wall thinning 21.06 16.94 4 25332 20 79719032
Hyperleukocytosis 20.90 16.94 12 25324 2598 79716454
Haemophagocytic lymphohistiocytosis 20.87 16.94 30 25306 21807 79697245
Urticaria 20.77 16.94 17 25319 185184 79533868
Atypical pneumonia 20.60 16.94 17 25319 6619 79712433
Enterococcal sepsis 20.41 16.94 12 25324 2714 79716338
Overgrowth fungal 20.23 16.94 5 25331 97 79718955
Allogenic stem cell transplantation 20.13 16.94 5 25331 99 79718953
Pulmonary mucormycosis 20.09 16.94 9 25327 1156 79717896
Herpes simplex reactivation 19.95 16.94 7 25329 472 79718580
Mobility decreased 19.85 16.94 7 25329 122168 79596884
Gait disturbance 19.82 16.94 22 25314 207484 79511568
Bordetella infection 19.68 16.94 5 25331 109 79718943
SARS-CoV-2 RNA 19.55 16.94 4 25332 31 79719021
Retinal haemorrhage 19.37 16.94 18 25318 8199 79710853
Blood pressure decreased 19.35 16.94 4 25332 99462 79619590
Cerebral toxoplasmosis 19.29 16.94 11 25325 2351 79716701
Respiratory syncytial virus infection 19.14 16.94 19 25317 9383 79709669
Cerebral ventricle collapse 19.14 16.94 5 25331 122 79718930
Cerebrovascular accident 19.03 16.94 13 25323 155279 79563773
Endophthalmitis 18.98 16.94 16 25320 6412 79712640
Pericardial effusion 18.98 16.94 44 25292 46193 79672859
Toxic skin eruption 18.97 16.94 29 25307 22264 79696788
Brain oedema 18.93 16.94 31 25305 25232 79693820
Peripheral sensory neuropathy 18.89 16.94 22 25314 13011 79706041
Cell death 18.83 16.94 14 25322 4685 79714367
Soft tissue infection 18.76 16.94 13 25323 3899 79715153
Polyomavirus-associated nephropathy 18.70 16.94 15 25321 5612 79713440
Candida sepsis 18.65 16.94 11 25325 2502 79716550
Brain compression 18.55 16.94 7 25329 581 79718471
Blast cell count increased 18.45 16.94 9 25327 1401 79717651
Wheezing 18.42 16.94 7 25329 116657 79602395
Citrobacter infection 18.36 16.94 8 25328 962 79718090
Myocardial infarction 18.16 16.94 19 25317 184110 79534942
Acute respiratory distress syndrome 18.16 16.94 42 25294 44025 79675027
Pneumonia cytomegaloviral 18.14 16.94 14 25322 4955 79714097
Migraine 18.13 16.94 3 25333 87490 79631562
Osteoarthritis 18.08 16.94 3 25333 87306 79631746
Stupor 18.06 16.94 16 25320 6856 79712196
Arthritis 17.96 16.94 7 25329 114873 79604179
Palpitations 17.77 16.94 9 25327 126601 79592451
Ureaplasma infection 17.75 16.94 8 25328 1042 79718010
Gastrointestinal tract mucosal pigmentation 17.75 16.94 8 25328 1042 79718010
Chronic obstructive pulmonary disease 17.54 16.94 3 25333 85416 79633636
Skin necrosis 17.51 16.94 25 25311 18062 79700990
Bacterial sepsis 17.50 16.94 17 25319 8181 79710871
Hypoxia 17.44 16.94 72 25264 103171 79615881
Streptococcal bacteraemia 17.34 16.94 12 25324 3594 79715458
Renal tubular acidosis 17.31 16.94 12 25324 3602 79715450
Febrile bone marrow aplasia 17.26 16.94 21 25315 12999 79706053
Pelvic venous thrombosis 17.20 16.94 10 25326 2215 79716837
Mucosal inflammation 17.18 16.94 58 25278 75522 79643530
Memory impairment 17.15 16.94 7 25329 111727 79607325
Encephalitis fungal 17.12 16.94 5 25331 186 79718866
Lymphopenia 17.10 16.94 33 25303 30524 79688528
Drug-induced liver injury 17.08 16.94 53 25283 66064 79652988
Intracranial mass 17.06 16.94 10 25326 2249 79716803
Pulmonary mass 17.04 16.94 32 25304 29002 79690050
Escherichia sepsis 16.97 16.94 17 25319 8491 79710561

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J02AC04 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOTICS FOR SYSTEMIC USE
ANTIMYCOTICS FOR SYSTEMIC USE
Triazole and tetrazole derivatives
FDA CS M0002083 Azoles
FDA EPC N0000175487 Azole Antifungal
MeSH PA D058888 14-alpha Demethylase Inhibitors
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000935 Antifungal Agents
MeSH PA D000977 Antiparasitic Agents
MeSH PA D000981 Antiprotozoal Agents
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006727 Hormone Antagonists
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances
MeSH PA D065088 Steroid Synthesis Inhibitors
MeSH PA D014344 Trypanocidal Agents
CHEBI has role CHEBI:36335 trypanocidal drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Mycosis indication 3218000 DOID:1564
Coccidioidomycosis indication 60826002 DOID:13450
Fusarium infection indication 64250002
Aspergillosis indication 65553006 DOID:13564
Mucormycosis indication 76627001
Candidiasis indication 78048006 DOID:1508
Candidiasis of mouth indication 79740000 DOID:14262
Chromoblastomycosis indication 187079000
Pharyngeal candidiasis indication 240704003
Mycetoma indication 410039003 DOID:13078




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Dogs Otitis externa caused by yeast, Malassezia pachydermatis Indication
Dogs Otitis externa associated with bacteria coagulase positive staphylococci Indication
Dogs Otitis externa associated with Pseudomonas aeruginosa Indication
Dogs Otitis externa associated with Enterococcus faecalis Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Posatex Otic Suspension Intervet Inc. 3

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.68 acidic
pKa2 5.12 Basic
pKa3 5.0 Basic
pKa4 2.66 Basic
pKa5 0.3 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
300MG/16.7ML (18MG/ML) NOXAFIL MERCK SHARP DOHME N205596 March 13, 2014 RX SOLUTION INTRAVENOUS 9358297 June 24, 2031 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WHO ARE SEVERELY IMMUNOCOMPROMISED
300MG/16.7ML (18MG/ML) NOXAFIL MERCK SHARP DOHME N205596 March 13, 2014 RX SOLUTION INTRAVENOUS 9358297 June 24, 2031 TREATMENT OF INVASIVE ASPERGILLOSIS IN ADULTS AND PEDIATRIC PATIENTS 13 YEARS OF AGE AND OLDER
300MG/16.7ML (18MG/ML) NOXAFIL MERCK SHARP DOHME N205596 March 13, 2014 RX SOLUTION INTRAVENOUS 9023790 July 4, 2031 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS
300MG/16.7ML (18MG/ML) NOXAFIL MERCK SHARP DOHME N205596 March 13, 2014 RX SOLUTION INTRAVENOUS 9023790 July 4, 2031 PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WHO ARE SEVERELY IMMUNOCOMPROMISED
300MG/16.7ML (18MG/ML) NOXAFIL MERCK SHARP DOHME N205596 March 13, 2014 RX SOLUTION INTRAVENOUS 9023790 July 4, 2031 TREATMENT OF INVASIVE ASPERGILLOSIS IN ADULTS AND PEDIATRIC PATIENTS 13 YEARS OF AGE AND OLDER

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
300MG/16.7ML (18MG/ML) POSACONAZOLE PAR STERILE PRODUCTS A208768 May 25, 2022 RX SOLUTION INTRAVENOUS Dec. 26, 2023 PATENT CHALLENGE
100MG NOXAFIL MERCK SHARP DOHME N205053 Nov. 25, 2013 RX TABLET, DELAYED RELEASE ORAL May 31, 2024 NEW PATIENT POPULATION
300MG/16.7ML (18MG/ML) NOXAFIL MERCK SHARP DOHME N205596 March 13, 2014 RX SOLUTION INTRAVENOUS May 31, 2024 NEW PATIENT POPULATION
300MG NOXAFIL POWDERMIX KIT MSD MERCK CO N214770 May 31, 2021 RX FOR SUSPENSION, DELAYED RELEASE ORAL May 31, 2024 NEW PRODUCT
100MG NOXAFIL MERCK SHARP DOHME N205053 Nov. 25, 2013 RX TABLET, DELAYED RELEASE ORAL June 17, 2024 FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN PATIENTS 13 YEARS OF AGE AND OLDER
300MG/16.7ML (18MG/ML) NOXAFIL MERCK SHARP DOHME N205596 March 13, 2014 RX SOLUTION INTRAVENOUS June 17, 2024 FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN PATIENTS 13 YEARS OF AGE AND OLDER
100MG NOXAFIL MERCK SHARP DOHME N205053 Nov. 25, 2013 RX TABLET, DELAYED RELEASE ORAL June 17, 2028 FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN ADULTS AND PEDIATRIC PATIENTS 13 YEARS OF AGE AND OLDER
300MG/16.7ML (18MG/ML) NOXAFIL MERCK SHARP DOHME N205596 March 13, 2014 RX SOLUTION INTRAVENOUS June 17, 2028 FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN ADULTS AND PEDIATRIC PATIENTS 13 YEARS OF AGE AND OLDER

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
ATP-binding cassette sub-family G member 2 Transporter IC50 5.22 CHEMBL
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase Enzyme IC50 5.42 CHEMBL
Cytochrome P450 3A4 Enzyme WOMBAT-PK
Lanosterol 14-alpha demethylase Enzyme INHIBITOR MIC 9.40 WOMBAT-PK CHEMBL
14-alpha sterol demethylase Cyp51A Enzyme Kd 5.57 CHEMBL
14-alpha sterol demethylase Enzyme Kd 7.14 CHEMBL
Sterol 14-alpha demethylase Enzyme IC50 7.32 CHEMBL
Sterol 14-alpha-demethylase Enzyme Kd 6.88 CHEMBL
14-alpha sterol demethylase Enzyme Kd 6.88 CHEMBL
14-alpha sterol demethylase Enzyme Kd 6.88 CHEMBL

External reference:

IDSource
4025699 VUID
N0000179745 NUI
D02555 KEGG_DRUG
4025699 VANDF
C0936148 UMLSCUI
CHEBI:64355 CHEBI
X2N PDB_CHEM_ID
CHEMBL1397 ChEMBL_ID
DB01263 DRUGBANK_ID
C101425 MESH_SUPPLEMENTAL_RECORD_UI
11428 IUPHAR_LIGAND_ID
7713 INN_ID
6TK1G07BHZ UNII
468595 PUBCHEM_CID
282446 RXNORM
21768 MMSL
320488 MMSL
83903 MMSL
d05853 MMSL
011210 NDDF
420282006 SNOMEDCT_US
421747003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
posaconazole HUMAN PRESCRIPTION DRUG LABEL 1 0054-0449 SUSPENSION 40 mg ORAL ANDA 30 sections
NOXAFIL HUMAN PRESCRIPTION DRUG LABEL 1 0085-1328 SUSPENSION 40 mg ORAL NDA 31 sections
NOXAFIL HUMAN PRESCRIPTION DRUG LABEL 1 0085-1328 SUSPENSION 40 mg ORAL NDA 31 sections
NOXAFIL HUMAN PRESCRIPTION DRUG LABEL 1 0085-1328 SUSPENSION 40 mg ORAL NDA 31 sections
NOXAFIL HUMAN PRESCRIPTION DRUG LABEL 1 0085-1328 SUSPENSION 40 mg ORAL NDA 31 sections
NOXAFIL HUMAN PRESCRIPTION DRUG LABEL 1 0085-2224 POWDER, FOR SUSPENSION 300 mg ORAL NDA 31 sections
NOXAFIL HUMAN PRESCRIPTION DRUG LABEL 1 0085-2224 POWDER, FOR SUSPENSION 300 mg ORAL NDA 31 sections
NOXAFIL HUMAN PRESCRIPTION DRUG LABEL 1 0085-2224 POWDER, FOR SUSPENSION 300 mg ORAL NDA 31 sections
NOXAFIL HUMAN PRESCRIPTION DRUG LABEL 1 0085-2224 POWDER, FOR SUSPENSION 300 mg ORAL NDA 31 sections
NOXAFIL HUMAN PRESCRIPTION DRUG LABEL 1 0085-4324 TABLET, COATED 100 mg ORAL NDA 31 sections
NOXAFIL HUMAN PRESCRIPTION DRUG LABEL 1 0085-4324 TABLET, COATED 100 mg ORAL NDA 31 sections
NOXAFIL HUMAN PRESCRIPTION DRUG LABEL 1 0085-4324 TABLET, COATED 100 mg ORAL NDA 31 sections
NOXAFIL HUMAN PRESCRIPTION DRUG LABEL 1 0085-4324 TABLET, COATED 100 mg ORAL NDA 31 sections
NOXAFIL HUMAN PRESCRIPTION DRUG LABEL 1 0085-4331 SOLUTION 18 mg INTRAVENOUS NDA 31 sections
NOXAFIL HUMAN PRESCRIPTION DRUG LABEL 1 0085-4331 SOLUTION 18 mg INTRAVENOUS NDA 31 sections
NOXAFIL HUMAN PRESCRIPTION DRUG LABEL 1 0085-4331 SOLUTION 18 mg INTRAVENOUS NDA 31 sections
NOXAFIL HUMAN PRESCRIPTION DRUG LABEL 1 0085-4331 SOLUTION 18 mg INTRAVENOUS NDA 31 sections
POSACONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 0254-1016 SUSPENSION 40 mg ORAL NDA authorized generic 32 sections
POSACONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 0254-2045 TABLET, COATED 100 mg ORAL NDA authorized generic 32 sections
POSACONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 0254-2045 TABLET, COATED 100 mg ORAL NDA authorized generic 32 sections
POSACONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 0254-2045 TABLET, COATED 100 mg ORAL NDA authorized generic 32 sections
POSACONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 0406-7711 TABLET, DELAYED RELEASE 100 mg ORAL ANDA 33 sections
POSACONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 0527-2133 TABLET, DELAYED RELEASE 100 mg ORAL ANDA 29 sections
POSACONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 0527-2133 TABLET, DELAYED RELEASE 100 mg ORAL ANDA 29 sections
POSACONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 0904-7149 TABLET, DELAYED RELEASE 100 mg ORAL ANDA 26 sections
POSACONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 0904-7149 TABLET, DELAYED RELEASE 100 mg ORAL ANDA 26 sections
POSACONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 0904-7149 TABLET, DELAYED RELEASE 100 mg ORAL ANDA 26 sections
POSACONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 16714-156 TABLET, DELAYED RELEASE 100 mg ORAL ANDA 29 sections
POSACONAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 16714-156 TABLET, DELAYED RELEASE 100 mg ORAL ANDA 29 sections
Posaconazole HUMAN PRESCRIPTION DRUG LABEL 1 16714-535 TABLET, DELAYED RELEASE 100 mg ORAL ANDA 26 sections